{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Zhou Y"],"pubmed_abstract":["Multiple types of liver diseases, particularly cholestatic liver diseases (CSLDs) and biliary diseases, can disturb bile acid (BA) secretion; however, BA accumulation is currently seen as an important incentive of various types of liver diseases' progression. Da-Chai-Hu decoction (DCHD) has long been used for treating cholestatic liver diseases; however, the exact mechanisms remain unclear. Currently, our study indicates that the liver damage and cholestasis status of the α-naphthylisothiocyanate (ANIT)-induced intrahepatic cholestasis and bile duct ligation (BDL)-induced extrahepatic cholestasis, following DCHD treatment, were improved; the changes of BA metabolism post-DCHD treatment were investigated by targeted metabolomics profiling by UPLC-MS/MS. DCHD treatment severely downregulated"],"journal":["Frontiers in pharmacology"],"pagination":["959074"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9437253"],"repository":["biostudies-literature"],"pubmed_title":["Targeted bile acid profiles reveal the liver injury amelioration of Da-Chai-Hu decoction against ANIT- and BDL-induced cholestasis."],"pmcid":["PMC9437253"],"pubmed_authors":["Li Y","He Y","Chen J","Chen L","Sun W","Zhou Y","Wang Z","Yao G","Niu X"],"additional_accession":[]},"is_claimable":false,"name":"Targeted bile acid profiles reveal the liver injury amelioration of Da-Chai-Hu decoction against ANIT- and BDL-induced cholestasis.","description":"Multiple types of liver diseases, particularly cholestatic liver diseases (CSLDs) and biliary diseases, can disturb bile acid (BA) secretion; however, BA accumulation is currently seen as an important incentive of various types of liver diseases' progression. Da-Chai-Hu decoction (DCHD) has long been used for treating cholestatic liver diseases; however, the exact mechanisms remain unclear. Currently, our study indicates that the liver damage and cholestasis status of the α-naphthylisothiocyanate (ANIT)-induced intrahepatic cholestasis and bile duct ligation (BDL)-induced extrahepatic cholestasis, following DCHD treatment, were improved; the changes of BA metabolism post-DCHD treatment were investigated by targeted metabolomics profiling by UPLC-MS/MS. DCHD treatment severely downregulated","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-21T14:26:21.63Z","creation":"2025-04-21T14:26:21.63Z"},"accession":"S-EPMC9437253","cross_references":{"pubmed":["36059946"],"doi":["10.3389/fphar.2022.959074"]}}